Bausch & Lomb
BLCOBausch & Lomb (since 2010 stylized as Bausch + Lomb) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
Drugs in Pipeline
81
Phase 3 Programs
63
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
9wMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
IDP-123 Lotion
Acne Vulgaris
Vehicle
Conjunctivitis, Allergic
Loteprednol Etabonate Gel (BID)
Inflammation
Bromfenac Ophthalmic Solution
Pain
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
Allergic Conjunctivitis
BTOS-HA
Ocular Redness
Bepreve (bepotastine besilate ophthalmic solution) 1.5%
Allergic Conjunctivitis
Vehicle of Loteprednol Etabonate
Inflammation
Vehicle of Ophthalmic Loteprednol Etabonate
Ocular Inflammation
Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
Chronic Hepatitis C
Tramadol HCl ER
Chronic Pain
Granulated mesalamine
Ulcerative Colitis
IDP-118 Lotion
Plaque Psoriasis
Rifaximin
Hepatic Encephalopathy
Plecanatide
Irritable Bowel Syndrome Characterized by Constipation
N-methylnaltrexone bromide (MOA-728)
Constipation
Balsalazide Disodium
Inflammatory Bowel Disease
IDP-122 Lotion
Plaque Psoriasis
Budesonide
Proctitis
Methylnaltrexone
Opioid-Induced Constipation
IDP-126 Gel
Acne Vulgaris
Larsucosterol
Hepatitis
brinzolamide 1% ophthalmic suspension
Glaucoma
0.5% Loteprednol Etabonate Ophthalmic Ointment
Ocular Inflammation
BOL-303259-X
Ocular Hypertension
Bromfenac
Postoperative Complications
Loteprednol etabonate
Cataract
Besivance
Bacterial Conjunctivitis
Loteprednol Etabonate Gel (TID)
Inflammation
EM-100
Allergic Conjunctivitis
Brimonidine Tartrate
Hyperemia
Latanoprostene bunod
Glaucoma
Bepotastine besilate
Seasonal Allergic Rhinitis
Ketotifen/naphazoline
Allergic Conjunctivitis
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Seasonal Allergic Conjunctivitis
Loteprednol Etabonate Ophthalmic Gel dosed TID
Cataract
Bromfenac Ophthalmic Solution A
Dry Eye Syndrome
Loteprednol etabonate 0.2%
Seasonal Allergic Conjunctivitis
Vitrase
Pain
KetoNaph
Allergic Conjunctivitis
fluocinolone acetonide intravitreal implant
Non-infectious Uveitis
Mapracorat
Cataract
NOV03
Dry Eye Disease (DED)
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Ocular Redness
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
Allergic Conjunctivitis
T-PRED
Cataract
SC Methylnaltrexone
Advance Illness Patients With OIC
ISV-403
Acute Bacterial Conjunctivitis
Ecabet 2.83%
Dry Eye Syndromes
Rifaximin SSD
Hepatic Encephalopathy
Fluocinolone acetonide 2.1mg
Noninfectious Posterior Uveitis
Sodium Fluorescein
Hyperemia
Naphazoline
Allergic Conjunctivitis
fluocinolone acetonide
Diabetic Macular Edema
Bepreve
Conjunctivitis, Allergic
Timolol
Open-Angle Glaucoma
crofelemer
Irritable Bowel Syndrome
MOA-728
Constipation
Loteprednol and tobramycin
Conjunctivitis
Prednisolone and Tobramycin
Eye Infections
Azopt 1%
Glaucoma
Pred Forte
Cataract
Besifloxacin
Acute Bacterial Conjunctivitis
bromfenac ophthalmic solution 0.06%
Dry Eye Disease
Bepotastine besilate formulation
Seasonal Allergic Rhinitis
Ecabet
Dry Eye Syndromes
Lotemax
Keratoconjunctivitis Sicca
0.59 mg fluocinolone acetonide intravitreal implant
Diabetic Macular Edema
Latanoprost
Intraocular Pressure
WB007 0.05%
Glaucoma, Primary Open Angle
BL1107 Low dose
Glaucoma
BOL-303242-X
Cataract
Bepotastine Besilate Nasal Spray 2% Twice a day
Seasonal Allergic Rhinitis
Loteprednol etabonate base (QD)
Allergic Conjunctivitis
PF-03187207 and Latanoprost Vehicle
Primary Open Angle Glaucoma
0.3% BOL-303242-X ophthalmic suspension
Dry Eye Syndrome
PF-03187207
Primary Open Angle Glaucoma
bepotastine besilate nasal product - low dose
Seasonal Allergic Rhinitis
ecabet ophthalmic solution
Dry Eye Disease
bepotastine besilate ophthalmic solution
Allergic Conjunctivitis
loteprednol etabonate ophthalmic suspension, 0.5%
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IDP-123 Lotion | Phase 3 | Acne Vulgaris | - | - |
Vehicle | Phase 3 | Conjunctivitis, Allergic | - | - |
Loteprednol Etabonate Gel (BID) | Phase 3 | Inflammation | - | - |
Bromfenac Ophthalmic Solution | Phase 3 | Pain | - | - |
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo) | Phase 3 | Allergic Conjunctivitis | - | - |
BTOS-HA | Phase 3 | Ocular Redness | - | - |
Bepreve (bepotastine besilate ophthalmic solution) 1.5% | Phase 3 | Allergic Conjunctivitis | - | - |
Vehicle of Loteprednol Etabonate | Phase 3 | Inflammation | - | - |
Vehicle of Ophthalmic Loteprednol Etabonate | Phase 3 | Ocular Inflammation | - | - |
Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks | Phase 3 | Chronic Hepatitis C | - | - |
Tramadol HCl ER | Phase 3 | Chronic Pain | - | - |
Granulated mesalamine | Phase 3 | Ulcerative Colitis | - | - |
IDP-118 Lotion | Phase 3 | Plaque Psoriasis | - | - |
Rifaximin | Phase 3 | Hepatic Encephalopathy | - | - |
Plecanatide | Phase 3 | Irritable Bowel Syndrome Characterized by Constipation | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
Balsalazide Disodium | Phase 3 | Inflammatory Bowel Disease | - | - |
IDP-122 Lotion | Phase 3 | Plaque Psoriasis | - | - |
Budesonide | Phase 3 | Proctitis | - | - |
Methylnaltrexone | Phase 3 | Opioid-Induced Constipation | - | - |
IDP-126 Gel | Phase 3 | Acne Vulgaris | - | - |
Larsucosterol | Phase 3 | Hepatitis | - | - |
brinzolamide 1% ophthalmic suspension | Phase 3 | Glaucoma | - | - |
0.5% Loteprednol Etabonate Ophthalmic Ointment | Phase 3 | Ocular Inflammation | - | - |
BOL-303259-X | Phase 3 | Ocular Hypertension | - | - |
Bromfenac | Phase 3 | Postoperative Complications | - | - |
Loteprednol etabonate | Phase 3 | Cataract | - | - |
Besivance | Phase 3 | Bacterial Conjunctivitis | - | - |
Loteprednol Etabonate Gel (TID) | Phase 3 | Inflammation | - | - |
EM-100 | Phase 3 | Allergic Conjunctivitis | - | - |
Brimonidine Tartrate | Phase 3 | Hyperemia | - | - |
Latanoprostene bunod | Phase 3 | Glaucoma | - | - |
Bepotastine besilate | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Ketotifen/naphazoline | Phase 3 | Allergic Conjunctivitis | - | - |
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
Loteprednol Etabonate Ophthalmic Gel dosed TID | Phase 3 | Cataract | - | - |
Bromfenac Ophthalmic Solution A | Phase 3 | Dry Eye Syndrome | - | - |
Loteprednol etabonate 0.2% | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
Vitrase | Phase 3 | Pain | - | - |
KetoNaph | Phase 3 | Allergic Conjunctivitis | - | - |
fluocinolone acetonide intravitreal implant | Phase 3 | Non-infectious Uveitis | - | - |
Mapracorat | Phase 3 | Cataract | - | - |
NOV03 | Phase 3 | Dry Eye Disease (DED) | - | - |
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation | Phase 3 | Ocular Redness | - | - |
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% | Phase 3 | Allergic Conjunctivitis | - | - |
T-PRED | Phase 3 | Cataract | - | - |
SC Methylnaltrexone | Phase 3 | Advance Illness Patients With OIC | - | - |
ISV-403 | Phase 3 | Acute Bacterial Conjunctivitis | - | - |
Ecabet 2.83% | Phase 3 | Dry Eye Syndromes | - | - |
Rifaximin SSD | Phase 3 | Hepatic Encephalopathy | - | - |
Fluocinolone acetonide 2.1mg | Phase 3 | Noninfectious Posterior Uveitis | - | - |
Sodium Fluorescein | Phase 3 | Hyperemia | - | - |
Naphazoline | Phase 3 | Allergic Conjunctivitis | - | - |
fluocinolone acetonide | Phase 3 | Diabetic Macular Edema | - | - |
Bepreve | Phase 3 | Conjunctivitis, Allergic | - | - |
Timolol | Phase 3 | Open-Angle Glaucoma | - | - |
crofelemer | Phase 3 | Irritable Bowel Syndrome | - | - |
MOA-728 | Phase 3 | Constipation | - | - |
Loteprednol and tobramycin | Phase 3 | Conjunctivitis | - | - |
Prednisolone and Tobramycin | Phase 3 | Eye Infections | - | - |
Azopt 1% | Phase 3 | Glaucoma | - | - |
Pred Forte | Phase 3 | Cataract | - | - |
Besifloxacin | Phase 3 | Acute Bacterial Conjunctivitis | - | - |
bromfenac ophthalmic solution 0.06% | Phase 2 | Dry Eye Disease | - | - |
Bepotastine besilate formulation | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Ecabet | Phase 2 | Dry Eye Syndromes | - | - |
Lotemax | Phase 2 | Keratoconjunctivitis Sicca | - | - |
0.59 mg fluocinolone acetonide intravitreal implant | Phase 2 | Diabetic Macular Edema | - | - |
Latanoprost | Phase 2 | Intraocular Pressure | - | - |
WB007 0.05% | Phase 2 | Glaucoma, Primary Open Angle | - | - |
BL1107 Low dose | Phase 2 | Glaucoma | - | - |
BOL-303242-X | Phase 2 | Cataract | - | - |
Bepotastine Besilate Nasal Spray 2% Twice a day | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Loteprednol etabonate base (QD) | Phase 2 | Allergic Conjunctivitis | - | - |
PF-03187207 and Latanoprost Vehicle | Phase 2 | Primary Open Angle Glaucoma | - | - |
0.3% BOL-303242-X ophthalmic suspension | Phase 2 | Dry Eye Syndrome | - | - |
PF-03187207 | Phase 2 | Primary Open Angle Glaucoma | - | - |
bepotastine besilate nasal product - low dose | Phase 2 | Seasonal Allergic Rhinitis | - | - |
ecabet ophthalmic solution | Phase 2 | Dry Eye Disease | - | - |
bepotastine besilate ophthalmic solution | Phase 2 | Allergic Conjunctivitis | - | - |
loteprednol etabonate ophthalmic suspension, 0.5% | Phase 2 | Dry Eye | - | - |